|LETTER TO EDITOR
|Year : 2022 | Volume
| Issue : 4 | Page : 1023
Ergotamine, headache, and COVID-19
Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2
1 26 Medical Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Tropical Medicine, Hainan Medical University, Haikou, China
|Date of Submission||15-Apr-2020|
|Date of Decision||28-May-2020|
|Date of Acceptance||13-Oct-2020|
|Date of Web Publication||10-Feb-2023|
Dr. Rujittika Mungmunpuntipantip
26 Medical Center, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mungmunpuntipantip R, Wiwanitkit V. Ergotamine, headache, and COVID-19. J Datta Meghe Inst Med Sci Univ 2022;17:1023
COVID-19 pandemic is a global public health problem. Medical professional has to recognize and adjust current medical practice to correspond to this emerging infectious disease. In clinical neurology, an important consideration is the use of drug for the management of patient. Of several problems, migraine is an important common medical disorder.
Silvestro et al. noted that a good plan for drug administration for controlling of migraine of the patients during the new disease outbreak was necessary.
In clinical practice, a commonly used drug for the management of migraine is ergotamine. The interrelationship between ergotamine and COVID-19 is interesting. To clarify this issue, the authors hereby perform an interaction pathway analysis by standard bioinformatics technique as used in the previous study. The interrelation analysis on the pharmacological pathway and pathogenesis pathway of coronavirus infection can show a common node at serotonin (5-HT) receptor. It seems that ergotamine might have unwanted effect against coronavirus [Figure 1]. In brief, ergotamine acts at the 5-HT 1B and 5-HT 1D receptors and 5-HT signaling influences cellular activities that regulate the entry of coronavirus into cell.
|Figure 1: Interaction pathway analysis for ergotamine and coronavirus infection|
Click here to view
Nevertheless, we would like to present additional data from only one from 2473 COVID-19 patients in Thailand (April 11, 2020) who have concurrent COVID-19 and migraine. In this case, ergotamine use did not cause any clinical problem (this case is still hospitalization).
The interrelationship between ergotamine, headache, and COVID-19 is an interesting topic for further research in clinical neurology.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Silvestro M, Tessitore A, Tedeschi G, Russo A. Migraine in the time of COVID-19. Headache 2020;60:988-9.
Wiwanitkit V. Interaction between leptin and leptin receptor in gastric carcinoma: Gene ontology analysis. Rev Esp Enferm Dig 2007;99:201-5.
Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache 2003;43:144-66.
Mainou BA, Ashbrook AW, Smith EC, Dorset DC, Denison MR, Dermody TS. Serotonin receptor agonist 5-nonyloxytryptamine alters the kinetics of reovirus cell Entry. J Virol 2015;89:8701-12.